Sucampo, Takeda Begin Global Phase 3 Programme of Lubiprostone in Paediatric

Sucampo, Takeda begin global phase 3 programme of lubiprostone in paediatric
"There is an unmet need for alternatives to traditional laxative therapy in the paediatric population, and there are currently no prescription products indicated for long-term use in this population. We look forward to conducting this study to …
Read more on pharmabiz.com

Sucampo and Takeda Initiate Global Pivotal Phase 3 Program of Lubiprostone in
BETHESDA, Md. and DEERFIELD, Ill., Dec. 17, 2013 (GLOBE NEWSWIRE) — Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) ("Sucampo") and its development and commercialization partner Takeda Pharmaceuticals ("Takeda") today announced the initiation of a global …
Read more on GlobeNewswire (press release)

Related Methadone Clinical Use Information…